252 related articles for article (PubMed ID: 19620134)
1. Rules-based HIV-1 genotypic resistance interpretation systems predict 8 week and 24 week virological antiretroviral treatment outcome and benefit from drug potency weighting.
Zazzi M; Prosperi M; Vicenti I; Di Giambenedetto S; Callegaro A; Bruzzone B; Baldanti F; Gonnelli A; Boeri E; Paolini E; Rusconi S; Giacometti A; Maggiolo F; Menzo S; De Luca A;
J Antimicrob Chemother; 2009 Sep; 64(3):616-24. PubMed ID: 19620134
[TBL] [Abstract][Full Text] [Related]
2. Construction, training and clinical validation of an interpretation system for genotypic HIV-1 drug resistance based on fuzzy rules revised by virological outcomes.
De Luca A; Vendittelli M; Baldini F; Di Giambenedetto S; Trotta MP; Cingolani A; Bacarelli A; Gori C; Perno CF; Antinori A; Ulivi G
Antivir Ther; 2004 Aug; 9(4):583-93. PubMed ID: 15456090
[TBL] [Abstract][Full Text] [Related]
3. Investigation of expert rule bases, logistic regression, and non-linear machine learning techniques for predicting response to antiretroviral treatment.
Prosperi MC; Altmann A; Rosen-Zvi M; Aharoni E; Borgulya G; Bazso F; Sönnerborg A; Schülter E; Struck D; Ulivi G; Vandamme AM; Vercauteren J; Zazzi M;
Antivir Ther; 2009; 14(3):433-42. PubMed ID: 19474477
[TBL] [Abstract][Full Text] [Related]
4. A genotypic drug resistance interpretation algorithm that significantly predicts therapy response in HIV-1-infected patients.
Van Laethem K; De Luca A; Antinori A; Cingolani A; Perna CF; Vandamme AM
Antivir Ther; 2002 Jun; 7(2):123-9. PubMed ID: 12212924
[TBL] [Abstract][Full Text] [Related]
5. Variability in the interpretation of transmitted genotypic HIV-1 drug resistance and prediction of virological outcomes of the initial HAART by distinct systems.
De Luca A; Cozzi-Lepri A; Perno CF; Balotta C; Di Giambenedetto S; Poggio A; Pagano G; Tositti G; Piscopo R; Del Forno A; Chiodo F; Magnani G; d'Arminio Monforte A; ;
Antivir Ther; 2004 Oct; 9(5):743-52. PubMed ID: 15535412
[TBL] [Abstract][Full Text] [Related]
6. Modelled in vivo HIV fitness under drug selective pressure and estimated genetic barrier towards resistance are predictive for virological response.
Deforche K; Cozzi-Lepri A; Theys K; Clotet B; Camacho RJ; Kjaer J; Van Laethem K; Phillips A; Moreau Y; Lundgren JD; Vandamme AM;
Antivir Ther; 2008; 13(3):399-407. PubMed ID: 18572753
[TBL] [Abstract][Full Text] [Related]
7. Virologic therapy response significantly correlates with the number of active drugs as evaluated using a LiPA HIV-1 resistance scoring system.
Ziermann R; Celis L; Derdelinckx I; Lambert C; Veeck J; Rizzo MG; Vanderborght B; Zissis G; Clumeck N; Fransen K; Vaira D; Hendricks D; Van Laethem K; Vandamme AM; Schmit JC; Knechten H; De Luca A; Louwagie J; Segers P; De Boeck K; Pottel H; De Brauwer A; Hulstaert F
J Clin Virol; 2004 Dec; 31 Suppl 1():S7-15. PubMed ID: 15567089
[TBL] [Abstract][Full Text] [Related]
8. A randomized controlled trial to evaluate antiretroviral salvage therapy guided by rules-based or phenotype-driven HIV-1 genotypic drug-resistance interpretation with or without concentration-controlled intervention: the Resistance and Dosage Adapted Regimens (RADAR) study.
Torti C; Quiros-Roldan E; Regazzi M; De Luca A; Mazzotta F; Antinori A; Ladisa N; Micheli V; Orani A; Patroni A; Villani P; Lo Caputo S; Moretti F; Di Giambenedetto S; Castelnuovo F; Maggi P; Tinelli C; Carosi G;
Clin Infect Dis; 2005 Jun; 40(12):1828-36. PubMed ID: 15909273
[TBL] [Abstract][Full Text] [Related]
9. Variable prediction of antiretroviral treatment outcome by different systems for interpreting genotypic human immunodeficiency virus type 1 drug resistance.
De Luca A; Cingolani A; Di Giambenedetto S; Trotta MP; Baldini F; Rizzo MG; Bertoli A; Liuzzi G; Narciso P; Murri R; Ammassari A; Perno CF; Antinori A
J Infect Dis; 2003 Jun; 187(12):1934-43. PubMed ID: 12792870
[TBL] [Abstract][Full Text] [Related]
10. Genotypic resistance tests in the management of the HIV-infected patient at virological failure.
Aceti A; Carosi G
Scand J Infect Dis Suppl; 2003; 106():61-6. PubMed ID: 15000587
[TBL] [Abstract][Full Text] [Related]
11. Prediction of early and confirmed virological response by genotypic inhibitory quotients for lopinavir in patients naïve for lopinavir with limited exposure to previous protease inhibitors.
Torti C; Uccelli MC; Quiros-Roldan E; Gargiulo F; Tirelli V; Lapadula G; Regazzi M; Pierotti P; Tinelli C; De Luca A; Patroni A; Manca N; Carosi G
J Clin Virol; 2006 Apr; 35(4):414-9. PubMed ID: 16280255
[TBL] [Abstract][Full Text] [Related]
12. The ability of four genotypic interpretation systems to predict virological response to ritonavir-boosted protease inhibitors.
Fox ZV; Geretti AM; Kjaer J; Dragsted UB; Phillips AN; Gerstoft J; Staszewski S; Clotet B; von Wyl V; Lundgren JD
AIDS; 2007 Oct; 21(15):2033-42. PubMed ID: 17885293
[TBL] [Abstract][Full Text] [Related]
13. Predicting the response to combination antiretroviral therapy: retrospective validation of geno2pheno-THEO on a large clinical database.
Altmann A; Däumer M; Beerenwinkel N; Peres Y; Schülter E; Büch J; Rhee SY; Sönnerborg A; Fessel WJ; Shafer RW; Zazzi M; Kaiser R; Lengauer T
J Infect Dis; 2009 Apr; 199(7):999-1006. PubMed ID: 19239365
[TBL] [Abstract][Full Text] [Related]
14. Differences of nine drug resistance interpretation systems in predicting short-term therapy outcomes of treatment-experienced HIV-1 infected patients: a retrospective observational cohort study.
Helm M; Walter H; Ehret R; Schmit JC; Kurowski M; Knechten H; Korn K; Braun P; Schmidt B
Eur J Med Res; 2007 Jun; 12(6):231-42. PubMed ID: 17666312
[TBL] [Abstract][Full Text] [Related]
15. A longitudinal analysis of healthcare costs after treatment optimization following genotypic antiretroviral resistance testing: does resistance testing pay off?
Simcock M; Sendi P; Ledergerber B; Keller T; Schüpbach J; Battegay M; Günthard HF;
Antivir Ther; 2006; 11(3):305-14. PubMed ID: 16759046
[TBL] [Abstract][Full Text] [Related]
16. Improved prediction of salvage antiretroviral therapy outcomes using ultrasensitive HIV-1 drug resistance testing.
Pou C; Noguera-Julian M; Pérez-Álvarez S; García F; Delgado R; Dalmau D; Álvarez-Tejado M; Gonzalez D; Sayada C; Chueca N; Pulido F; Ibáñez L; Rodríguez C; Casadellà M; Santos JR; Ruiz L; Clotet B; Paredes R
Clin Infect Dis; 2014 Aug; 59(4):578-88. PubMed ID: 24879788
[TBL] [Abstract][Full Text] [Related]
17. The development of an expert system to predict virological response to HIV therapy as part of an online treatment support tool.
Revell AD; Wang D; Boyd MA; Emery S; Pozniak AL; De Wolf F; Harrigan R; Montaner JS; Lane C; Larder BA;
AIDS; 2011 Sep; 25(15):1855-63. PubMed ID: 21785323
[TBL] [Abstract][Full Text] [Related]
18. The development of artificial neural networks to predict virological response to combination HIV therapy.
Larder B; Wang D; Revell A; Montaner J; Harrigan R; De Wolf F; Lange J; Wegner S; Ruiz L; Pérez-Elías MJ; Emery S; Gatell J; Monforte AD; Torti C; Zazzi M; Lane C
Antivir Ther; 2007; 12(1):15-24. PubMed ID: 17503743
[TBL] [Abstract][Full Text] [Related]
19. Virological response to salvage therapy in HIV-infected persons carrying the reverse transcriptase K65R mutation.
Antinori A; Trotta MP; Lorenzini P; Torti C; Gianotti N; Maggiolo F; Ceccherini-Silberstein F; Nasto P; Castagna A; De Luca A; Mussini C; Andreoni M; Perno CF;
Antivir Ther; 2007; 12(8):1175-83. PubMed ID: 18240858
[TBL] [Abstract][Full Text] [Related]
20. A comparison of three computational modelling methods for the prediction of virological response to combination HIV therapy.
Wang D; Larder B; Revell A; Montaner J; Harrigan R; De Wolf F; Lange J; Wegner S; Ruiz L; Pérez-Elías MJ; Emery S; Gatell J; D'Arminio Monforte A; Torti C; Zazzi M; Lane C
Artif Intell Med; 2009 Sep; 47(1):63-74. PubMed ID: 19524413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
